Vishwamitra Futures
Issue #014
Gene editing is no longer only a laboratory debate. India’s public rice varieties, a major humanitarian CRISPR licence and the European Union’s new two-tier rules have moved the question from molecular capability to institutional design: who owns the seed, who can access it, and who bears the risk.
By Santhosh Vishwamitra
Current Drivers
CONFIRMED: On 30 March 2022 India issued an Office Memorandum that allows developers of foreign-DNA-free SDN-1 and SDN-2 genome-edited plants to seek exemption from specified GMO rules after institutional biosafety and national review. In May 2025 the Indian Council of Agricultural Research announced two genome-edited rice varieties developed through public institutions - DRR Dhan 100 (Kamala) and Pusa DST Rice 1, stating that each had undergone independent multilocation testing at more than fifty locations during 2023 and 2024.
CONFIRMED: The European Union adopted Regulation (EU) 2026/1388 on 17 June 2026. It entered into force on 16 July 2026 and is scheduled to apply from 17 July 2028. The regulation creates differentiated pathways: lighter treatment for less-complex NGT plants that could also have been produced by conventional breeding, and stricter authorisation for more extensively modified plants.
REPORTED / CONFIRMED on institutional access: In mid-to-late September 2026 coverage, ICRISAT secured long-term humanitarian, non-exclusive access to the CRISPR-Cas9 patent portfolio held by Corteva Agriscience and the Broad Institute. The licence covers mandate dryland crops like pulses, millets, oilseeds, sorghum, chickpea, pigeonpea and groundnut, with the stated aim of climate resilience and smallholder systems in Asia and Africa. Primary announcement of the arrangement occurred earlier, in August 2026.
Simultaneously, the Samyukt Kisan Morcha has issued a public warning against commercial release and multiplication of the Indian gene-edited rice lines, citing patent control, undisclosed licensing terms, biosafety concerns and performance questions relative to parent and indigenous lines. In Europe, small-farm organisations including the German AbL have signalled legal challenges focused on market-structure and coexistence effects of the NGT framework.
These are not isolated technical events. They are living tests of the same underlying design problem: technical access and lighter regulation do not automatically translate into affordable on-farm delivery or equitable benefit.
Realistic Future Situation
By the late 2020s the global agricultural biotechnology landscape is likely to remain fragmented. India will continue to operate a differentiated pathway for foreign-DNA-free edits while farmers, seed companies and export markets negotiate the practical meaning of that pathway. The European Union will implement its two-tier system, with secondary rules on verification, labelling, traceability and coexistence still under development. Public and CGIAR institutions will attempt to convert humanitarian licences into actual varieties that can be multiplied and delivered through national systems.
The decisive intermediate variables will not be the molecular precision of the edit itself. They will be:
- ownership and licensing terms of the resulting varieties;
- downstream seed-multiplication capacity for non-commercial crops in fragmented smallholder systems;
- interaction with informal and peasant seed economies (saving, exchange, local adaptation);
- farm-level net income after seed costs, input changes, price volatility and supplier dependence;
- post-release ecological monitoring and liability rules;
- trade and traceability friction under divergent product-based and residual process-based classifications.
National Academies evidence on earlier genetically engineered crops already showed that yield, cost and environmental outcomes vary with pest pressure, management practices, infrastructure and market access. Gene editing does not erase that context dependence. It can lower certain research and development costs and accelerate some trait development, but it does not guarantee that the resulting varieties will be affordable, locally adapted or net-profitable for the farmers who need them most.
Trajectory Mapping
Three institutional models are now running in parallel.
Public-sector development (India’s rice pathway). Public institutions develop and test varieties under a lighter regulatory track for foreign-DNA-free edits. The open question is whether the resulting seed remains broadly accessible or becomes embedded in commercial licensing systems that restrict saving, exchange or independent breeding.
Humanitarian licensing (ICRISAT–Corteva–Broad). A major CGIAR centre obtains portfolio access for specified dryland crops. Technical access is unblocked for public and partner programmes. The open question is the fine print: royalties, field-of-use limits, sub-licensing rights to national systems, and whether farmer seed-saving is preserved or constrained.
Two-tier market regulation (EU NGT framework). A major consumer and export market creates differentiated legal treatment while retaining risk assessment for more complex categories. The open question is implementation: verification capacity, labelling, coexistence with organic and conventional systems, and the practical effect of patent transparency requirements that stopped short of substantive patent limits.
These models will interact. Indian varieties may face export classification problems in markets that treat certain edits as GMOs. Humanitarian licences may still leave royalty or stacking costs that raise barriers for resource-poor systems. EU secondary rules may shape what traits are commercially attractive for European planting and for exporters seeking EU market access.
Best Case
In the favourable trajectory, public-sector and humanitarian pathways succeed in delivering climate-resilient, disease-resistant and resource-efficient varieties of rice, millets, pulses and other mandate crops at prices and under terms that allow small and marginal farmers to adopt them without long-term seed dependence. Multilocation performance data, once fully independent and farm-budgeted, show net-income gains under realistic input and market conditions. Seed-saving rights remain intact for the varieties that matter most to informal systems. The EU’s lighter NGT-1 pathway accelerates useful traits without collapsing coexistence or transparency. Post-release monitoring detects early ecological problems and corrects them. Trade rules converge enough that exporters are not forced into costly dual systems. Gene editing functions as one tool among many for food security and climate adaptation rather than as a new enclosure of the seed supply.
This trajectory assumes that ownership remains substantially public or genuinely open-access for key varieties, that multiplication systems for non-commercial crops are adequately funded and managed, and that farm-level economics — not laboratory yield claims — remain the performance metric.
Most Likely
The more probable path is partial and uneven. India’s genome-edited rice varieties reach limited commercial or semi-commercial release in some regions. Performance under stress is real in trial conditions but variable on farm; net income gains appear for better-resourced farmers with reliable irrigation, credit and market access, while smaller operators face higher seed costs or limited extension support. ICRISAT and partner programmes convert the CRISPR licence into breeding pipelines for selected mandate crops, yet multiplication and delivery remain slower and thinner than the technical capability would allow. Precise licence terms stay only partly public; royalty and field-of-use constraints quietly shape what national systems can do.
In the European Union the two-tier system becomes operational after 2028. Simple edits move faster; more complex traits remain under heavier authorisation. Small-farm legal challenges and organic-sector exclusion continue to generate friction. Patent transparency improves information without materially altering concentration in key trait markets. Trade fragmentation persists: exporters to both India and the EU must navigate divergent classifications, raising costs and discouraging some otherwise useful varieties.
Overall, gene editing expands the technical toolkit and produces measurable gains in selected crops and regions, yet does not resolve seed-market concentration or guarantee that climate-resilient traits reach the farmers most exposed to drought, salinity and disease pressure. The institutional intermediate layer remains the binding constraint.
Worst Case
In the adverse trajectory, lighter regulation and humanitarian framing become cover for accelerated concentration. Public varieties are released under opaque commercial terms that restrict saving or independent breeding. Humanitarian licences contain royalty, stacking or field-of-use clauses that effectively lock national systems into dependency. Independent multi-location and net-income data remain scarce or contested; marketing claims outrun farm-budget evidence. Post-release ecological monitoring is weak. Trade rules diverge further, creating practical barriers for food-exporting countries. Farmer organisations escalate opposition, reducing political space for even well-designed public programmes. Gene editing delivers commercial traits for capital-intensive systems while smallholder and dryland crops remain underserved, and the technology becomes associated with a new form of technological dependence rather than with food-security resilience.
This path is not inevitable. It becomes more likely if ownership and licence fine print are treated as secondary, if farm-level economics are ignored, and if regulatory light-touch is equated with automatic public benefit.
Consequences for Ordinary People
For small and marginal farmers the practical questions are concrete: Will the seed cost more than the yield or risk reduction justifies? Can the variety be saved and exchanged within local systems, or does each season require repurchase? Are extension services and complementary inputs available? Will the grain sell without discount or market rejection?
For consumers the questions are different but related: Will labelling and traceability provide meaningful information? Will regulatory divergence raise food prices or limit variety? Will the traits that reach markets prioritise storage, appearance and shelf life over nutrition or local adaptation?
For public institutions and national research systems the stakes are strategic: Can they retain breeding capacity and access to enabling technologies without becoming permanent licensees of a small number of patent holders? Can they prioritise traits that commercial markets undervalue — drought tolerance in orphan crops, reduced mycotoxin risk, lower water demand, without surrendering control of the resulting varieties?
These are not abstract ethical questions. They determine whether gene editing expands or contracts the real options available to the people who grow and eat the food.
What Could Change the Scenario
Several near-term decisions can materially shift the trajectories:
- Formal commercial-release or large-scale multiplication decisions on India’s gene-edited rice lines, together with transparent performance and net-income data under commercial conditions.
- Publication or leakage of the precise commercial terms of the ICRISAT–Corteva–Broad arrangement (royalties, field-of-use, sub-licensing, seed-saving provisions).
- Further expansion or restriction of humanitarian or public-sector access to enabling patents.
- EU secondary legislation and any interim court rulings on patent, coexistence and labelling elements of the NGT framework.
- Independent multi-location and farm-budget studies that move beyond trial yield claims.
- Demonstrable seed-multiplication and delivery systems for non-commercial crops in Asia and Africa.
None of these events is certain. Each would supply evidence that either strengthens or weakens the claim that gene editing can serve food security and climate resilience without increasing technological dependence.
Core Deductions
- Gene editing has moved from prospective technology debate into governance and deployment. India’s public rice pathway, the ICRISAT humanitarian licence and the EU two-tier NGT regulation are the current living tests.
- Technical access and regulatory light-touch do not automatically equal affordable on-farm delivery or smallholder benefit. Ownership, licence terms, seed-system capacity and farm-level net economics are the decisive intermediate variables.
- Existing evidence on genetically engineered crops supports trait- and context-specific assessment, not universal safety or universal benefit claims. The same discipline applies to gene-edited varieties.
- The most important coverage gap remains institutional design: who pays for development, who owns the seed, who can access it, who bears ecological risk, and how cross-border trade handles divergent legal classifications.
- Near-term decisions on Indian release, licence fine print, EU secondary rules and independent farm-budget data will determine which trajectory becomes more probable.
The Broader Horizon
The deeper question is not whether gene editing can change DNA at targeted locations. It can. The deeper question is whether the institutional arrangements now being built will treat that capability as a public instrument of climate resilience and food security or as another layer of control over seed, trait and market.
Public-sector development does not automatically equal open access. Humanitarian licensing does not automatically equal low-cost delivery. Lighter regulation does not automatically increase innovation that reaches the farmers most exposed to climate risk. Aggregate yield claims do not equal net farm income. These distinctions are not semantic. They decide the distribution of benefit and risk.
Gene editing will continue. The open variable is the quality of the institutions that surround it. India’s rice varieties, the ICRISAT licence and the EU’s two-tier rules are not the end of the story. They are the first concrete tests of whether the technology can be steered toward resilience without creating a new form of technological dependence in agriculture.
STAY CONNECTED
Vishwamitra Chronicles Network
Original reporting and analysis on science, geopolitics, history, and civilization.
Comments
Post a Comment